A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach

Michal Haran, Vita Mirkin, Andrei Braester, Nurith Harpaz, Olga Shevetz, Marina Shtreiter, Shulamit Greenberg, Orly Mordich, Orna Amram, Inbal Binsky-Ehrenreich, Ayelet Marom, Idit Shachar, Yair Herishanu, Rosa Ruchlemer, Alain Berrebi, Liora Valinsky, Mordechai Shtalrid, Lev Shvidel

Research output: Contribution to journalLetterpeer-review

14 Scopus citations
Original languageEnglish
Pages (from-to)125-128
Number of pages4
JournalBritish Journal of Haematology
Volume182
Issue number1
DOIs
StatePublished - Jul 2018
Externally publishedYes

Bibliographical note

Funding Information:
Haran designed the research, performed the research, analysed the data and wrote the paper. Mirkin performed the research, analysed the data and wrote the paper. Braester performed the research, Harpaz performed the research, Shvetz performed the research and wrote the paper, Shtreiter designed and performed the research, Greenberg, Amram, Mordich, Binsky, Marom performed the research, Ruchlemer and Herishanu provided essential reagents and tools, Shachar performed the research and wrote the paper, Valinsky analysed the data, Shtalrid (deceased) designed and performed the research, Shvidel designed the research and wrote the paper. The authors would like to thank the Israeli CLL study group for participation and support, Dr. David Goldenberg and Imunomedics for kindly providing the study medication. This study was funded by a grant from the Israel Cancer Association.

Keywords

  • Phase I clinical trial
  • chronic lymphocytic leukaemia
  • elderly patients
  • milatuzumab
  • performance status

Cite this